Singapore, March 4, 2009: SOHM, a generic pharmaceutical manufacturer, is expanding its generic drug distribution within the emerging pharmaceutical market in South East Asia; specifically in Indonesia, Thailand, the Philippines, and Malaysia. The company's direct manufacturing of generic pharmaceuticals is said to allow pricing advantages and distribution of quality drugs to consumers with limited access to medicine in this region.

SOHM is also said to be positioned to capitalize on the health issues not being addressed such as different contagious diseases and life style disorders such as cardiovascular, diabetes, musculoskeletal disorders and cancer to expand the market and serve the populations of these countries.

According to the company, South East Asia is the fourth-largest pharmaceutical market in the world, behind the US, Japan, and Europe. South East Asia is also the world's fastest-growing pharmaceutical market. Factors driving this market expansion include economic growth, a broadening middle class, growing and aging population, increasing economic liberalization, and an expanded government and private-sector role in improving health care.

Vice President for Corporate Strategy at SOHM, Mr Shailesh Shah said, "Pharmaceutical markets in South East Asia; Indonesia, the Philippines, Thailand, and Malaysia are all growing rapidly as people demand access to modern drugs and as these emerging economies expand. Despite the challenges in the current economic climate much of the populations of these countries have a great need for basic pharmaceuticals that are either too expensive or not available to vast populations in this region. SOHM fills this need and we are very excited to provide a valuable service to these countries and their citizens."